Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.

Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S500-8. doi: 10.1245/s10434-013-2882-0. Epub 2013 Feb 10.

PMID:
23397153
2.

Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement.

Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY.

Ann Surg Oncol. 2012 Nov;19(12):3659-67. doi: 10.1245/s10434-012-2610-1. Epub 2012 Sep 11.

PMID:
22965567
3.

Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?

Chen KT, Devarajan K, Milestone BN, Cooper HS, Denlinger C, Cohen SJ, Meyer JE, Hoffman JP.

Ann Surg Oncol. 2014 Feb;21(2):662-9. doi: 10.1245/s10434-013-3396-5. Epub 2013 Nov 26.

PMID:
24276638
4.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

5.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
6.

Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.

Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Am Coll Surg. 2014 Jul;219(1):111-20. doi: 10.1016/j.jamcollsurg.2014.02.023. Epub 2014 Mar 13.

PMID:
24856952
7.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW.

Ann Surg Oncol. 2011 Mar;18(3):619-27. doi: 10.1245/s10434-010-1456-7. Epub 2011 Jan 7.

PMID:
21213060
8.

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.

Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH.

Ann Surg Oncol. 2015 Jul;22(7):2416-23. doi: 10.1245/s10434-014-4285-2. Epub 2014 Dec 18.

PMID:
25519927
9.

Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.

Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH.

Ann Surg Oncol. 2012 Jun;19(6):2045-53. doi: 10.1245/s10434-011-2211-4. Epub 2012 Jan 19.

PMID:
22258816
10.

Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.

Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, Eisenberg B, Paul A, Hanks G.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7.

PMID:
8083109
11.

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR.

J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.

PMID:
22311829
12.

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB.

Ann Surg Oncol. 2001 Mar;8(2):123-32.

PMID:
11258776
13.

Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.

Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR, Viret F.

Eur J Surg Oncol. 2010 Oct;36(10):987-92. doi: 10.1016/j.ejso.2010.07.003. Epub 2010 Sep 9.

PMID:
20828979
14.

Treatment of clinical T2N0M0 esophageal cancer.

Hardacker TJ, Ceppa D, Okereke I, Rieger KM, Jalal SI, LeBlanc JK, DeWitt JM, Kesler KA, Birdas TJ.

Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.

PMID:
25047477
15.

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA.

J Clin Oncol. 2008 Jul 20;26(21):3496-502. doi: 10.1200/JCO.2007.15.8634.

16.

[Role of adjuvant chemoradiotherapy in the therapeutic strategy of exocrine adenocarcinoma of the pancreas].

Mornex F, Partensky C, Bedenne L.

Cancer Radiother. 1997;1(5):542-6. Review. French.

PMID:
9587387
17.

Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.

Greer SE, Pipas JM, Sutton JE, Zaki BI, Tsapakos M, Colacchio TA, Gibson JJ, Wiener DC, Ripple GH, Barth RJ Jr.

J Am Coll Surg. 2008 Mar;206(3):451-7. doi: 10.1016/j.jamcollsurg.2007.10.002. Epub 2007 Dec 27.

PMID:
18308215
18.

Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.

Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB.

Ann Surg Oncol. 2010 Jul;17(7):1794-801. doi: 10.1245/s10434-010-0943-1. Epub 2010 Feb 17.

19.

Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.

Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S.

Surgery. 2016 Mar;159(3):893-900. doi: 10.1016/j.surg.2015.09.018.

PMID:
26602840
20.

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B.

Radiother Oncol. 2014 Oct;113(1):41-6. doi: 10.1016/j.radonc.2014.09.010. Epub 2014 Oct 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk